Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00275
|
|||||
| Drug Name |
Bestatin
|
|||||
| Synonyms |
((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; AC1L972Z; AKOS026750073; BDBM50010142; Bestatin (TN); C00732; CHEBI:140702; CHEBI:3070; CHEMBL476869; D00087; DTXSID4048430; GTPL5151; NCGC00161660-01; SCHEMBL25971; SureCN25971; UPCMLD-DP116; UPCMLD-DP116:001; Ubenimex (JP16/INN); Ubenimex (JP17/INN); ZINC01532730; ZINC1532730
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute myeloid leukemia [ICD11: 2A60] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H24N2O4
|
|||||
| Canonical SMILES |
CC(C)CC(C(=O)O)NC(=O)C(C(CC1=CC=CC=C1)N)O
|
|||||
| InChI |
InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13-,14+/m1/s1
|
|||||
| InChIKey |
VGGGPCQERPFHOB-MCIONIFRSA-N
|
|||||
| CAS Number |
CAS 58970-76-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 308.37 | Topological Polar Surface Area | 113 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-1
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:3070
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | PEPT1 | Transporter Info | Km = 340 microM | Human enterocyte-like 2 cells (Caco-2)-PEPT1 | [2] | |
| References | ||||||
| 1 | Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival. Gan To Kagaku Ryoho. 2003 Aug;30(8):1113-8. | |||||
| 2 | Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol. 1993 Aug;265(2 Pt 1):G289-94. | |||||
| 3 | Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2. Am J Physiol Renal Physiol. 2008 Jun;294(6):F1422-32. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.